Ace the Enchondroma Examination Question: Diagnosis & Management

Key Takeaway
Looking for accurate information on Ace the Enchondroma Examination Question: Diagnosis & Management? An enchondroma is a benign, well-defined cartilaginous tumor often presenting as an expansile, lytic lesion with stippled calcification. For an examination question enchondroma, diagnosis requires a full history, physical exam, MRI, and bone tumor MDT discussion. Surgical treatment typically involves curettage. Malignant transformation is rare for solitary lesions but higher in enchondromatosis conditions.
A 45-year-old male presents with a dull, aching pain in his proximal humerus. Radiographs reveal an intramedullary lucent lesion with central punctate calcifications. Given this clinical presentation, how do you differentiate between a benign enchondroma and a low-grade chondrosarcoma?

Candidate: I would distinguish them based on clinical symptoms and imaging. Pain, especially new-onset or night pain, is more concerning for chondrosarcoma. On imaging, I would look for aggressive features like endosteal scalloping greater than two-thirds of the cortex, cortical breach, or associated soft tissue masses. I would also order an MRI to assess for perilesional edema, which is rarely seen in benign enchondromas.
Candidates often rely solely on the appearance of calcifications (e.g., "rings and arcs"). This is a mistake, as both benign and malignant cartilage tumors demonstrate this matrix. Failing to mention pain as a critical discriminator or neglecting the significance of cortical scalloping depth are also frequent errors that signify a lack of clinical nuance.
A high-scoring answer structures the differentiation into three pillars: 1. Clinical: Pain is the primary indicator of activity; asymptomatic lesions are likely benign. 2. Radiographic: Scalloping >2/3 of cortical thickness, cortical destruction, or periosteal reaction indicates malignancy. 3. Advanced Imaging: MRI to evaluate for soft tissue extension and T2-weighted signal intensity. Mentioning the IDH1/2 mutation profile and the necessity of histopathological correlation for equivocal cases demonstrates true mastery.